FOLH1 and prostate carcinoma: Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein consisting of 750 amino acids, is commonly overexpressed in almost all prostate cancer cells (Kiess et al. 2015; Haberkorn et al. 2016; Osborne et al. 2013).